WallStreetZenWallStreetZen

NASDAQ: THRD
Third Harmonic Bio Inc Stock

$4.71+0.05 (+1.07%)
Updated Jun 2, 2023
THRD Price
$4.71
Fair Value Price
N/A
Market Cap
$190.12M
52 Week Low
$3.75
52 Week High
$24.60
P/E
N/A
P/B
0.67x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.03
Operating Cash Flow
N/A
Beta
1.06
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

THRD Overview

Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was founded in 2019 and is headquartered in Cambridge, Massachusetts.

Zen Score

Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how THRD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

THRD is good value based on its book value relative to its share price (0.67x), compared to the US Biotechnology industry average (5.2x)
P/B vs Industry Valuation
THRD's short-term assets ($285.75M) exceed its short-term liabilities ($4.95M)
Short-term Liabilities Financials
THRD's short-term assets ($285.75M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more THRD due diligence checks available for Premium users.

Be the first to know about important THRD news, forecast changes, insider trades & much more!

THRD News

Valuation

THRD price to earnings (PE)

For valuing profitable companies with steady earnings
Company
0x
Industry
11.51x
Market
52.69x

THRD price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.67x
Industry
5.2x
THRD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

THRD's financial health

Profit margin

Revenue
$0.0
Net Income
-$9.1M
Profit Margin
0%

Assets to liabilities

Assets
$291.4M
Liabilities
$8.7M
Debt to equity
0.03
THRD's short-term assets ($285.75M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
THRD's short-term assets ($285.75M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
THRD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$6.7M
Investing
$0.0
Financing
$0.0

THRD vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
THRD$190.12M+1.07%N/A0.67x
FULC$189.60M+6.23%-1.38x0.64x
IFRX$188.49M-2.32%-6.39x2.18x
OCEA$187.07M-3.85%-1.51x121.16x
SLN$194.30M-5.43%N/A9.37x

Third Harmonic Bio Stock FAQ

What is Third Harmonic Bio's quote symbol?

(NASDAQ: THRD) Third Harmonic Bio trades on the NASDAQ under the ticker symbol THRD. Third Harmonic Bio stock quotes can also be displayed as NASDAQ: THRD.

If you're new to stock investing, here's how to buy Third Harmonic Bio stock.

What is the 52 week high and low for Third Harmonic Bio (NASDAQ: THRD)?

(NASDAQ: THRD) Third Harmonic Bio's 52-week high was $24.60, and its 52-week low was $3.75. It is currently -80.85% from its 52-week high and 25.6% from its 52-week low.

How much is Third Harmonic Bio's stock price per share?

(NASDAQ: THRD) Third Harmonic Bio stock price per share is $4.71 today (as of Jun 2, 2023).

What is Third Harmonic Bio's Market Cap?

(NASDAQ: THRD) Third Harmonic Bio's market cap is $190.12M, as of Jun 5, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Third Harmonic Bio's market cap is calculated by multiplying THRD's current stock price of $4.71 by THRD's total outstanding shares of 40,364,375.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.